3Heathcote EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatology,2000,31:1005-1013. 被引量：1
2Mitchison HC, Palmer JM, et al. A controlled trial of prednisolone treatment in primary, biliary cirrhosis: three-year results, J Hepatol, 1992,15:336-44. 被引量：1
3Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.Gastroenterology, 1993,104 : 519-26. 被引量：1
4Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology, 1991,101 : 1332-1338 被引量：1
5Kaplan M, Schmid C, McKusick A. et al. Double-blind trial of methotrexate (MTX) versus colchicine (COLCH) in primary biliary cirrhosis ( PBC). Hepatology, 1993,18(Suppl) : 176A. 被引量：1
6Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001.35: 134-146. 被引量：1
7Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatie liver disease: mechanisms of action and therapeutic: use revisited. Hepatology,1993,18 ( Suppl ) : 176A. 被引量：1
8Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology, 1995, 22:1158-1162. 被引量：1
9Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol, 2001, 35:134-146. 被引量：1
10Paumgarther G, Beuers U. Ursordeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology,2002, 36 : 525-531. 被引量：1
